Biosimulation

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Retrieved on: 
Monday, March 11, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Research, Software, General Health, Genetics, Health Technology, Science, Data Management, Clinical Trials, Biopsy, OS, HER2, Cancer, Radiation, Kingdom of Poland, Anthracycline, Survival, Disease, Neoadjuvant therapy, CBM, International Cancer Genome Consortium, TNM, University, Patient, Rated R, NGS, Biomarker, MSI, Artificial intelligence, Standard of care, DFS, TRI, MD, Medicine, TRG, Platinum, Publication, Biosimulation, OGA, Whole genome sequencing, PD-L1, Taxane, Medical imaging

The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).

Key Points: 
  • The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
  • Despite progress in gastroesophageal cancer therapy, only a small proportion of patients attain long-term survival.
  • This study concluded that TRI scores for gastroesophageal adenocarcinoma patients predict OS and DFS beyond clinical factors.
  • These results highlight the clinical value of employing Cellworks biosimulation for personalized therapy selection and warrant additional clinical evaluation.

Bio Simulation Market Expected to Reach USD 8.99 Billion by 2030: Verified Market Research®

Retrieved on: 
Thursday, April 13, 2023
Partnership, Drug development, Research, USD, Chemical Computing Group, Dassault Group, SWOT, Collection, Memorial Sloan Kettering Cancer Center, Geography, Growth, Benchmarking, Genedata, Pharmaceutical industry, Fine chemical, Biosimulation

JERSEY CITY, N.J., April 13, 2023 /PRNewswire/ -- The global Bio Simulation Market is projected to grow at a CAGR of 16.20% from 2023 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 2.33 Billion in 2021 and is expected to reach USD 8.99 Billion by the end of the forecast period.

Key Points: 
  • The report also provides an in-depth analysis of the global Bio Simulation Market, including its growth prospects, market trends, and market challenges
    JERSEY CITY, N.J., April 13, 2023 /PRNewswire/ -- The global Bio Simulation Market is projected to grow at a CAGR of 16.20% from 2023 to 2030, according to a new report published by Verified Market Research®.
  • The report reveals that the market was valued at USD 2.33 Billion in 2021 and is expected to reach USD 8.99 Billion by the end of the forecast period.
  • According to a new market research report published by Verified Market Research, the global biosimulation market is expected to grow at a CAGR of 16.20% during the forecast period of 2023-2030.
  • Based on the research, Verified Market Research® has segmented the global Bio Simulation Market into Product And Services, Application, End-User, And Geography.

Bio Simulation Market Expected to Reach USD 8.99 Billion by 2030: Verified Market Research®

Retrieved on: 
Thursday, April 13, 2023
Partnership, Drug development, Research, USD, Chemical Computing Group, Dassault Group, SWOT, Collection, Memorial Sloan Kettering Cancer Center, Geography, Growth, Benchmarking, Genedata, Pharmaceutical industry, Fine chemical, Biosimulation

JERSEY CITY, N.J., April 13, 2023 /PRNewswire/ -- The global Bio Simulation Market is projected to grow at a CAGR of 16.20% from 2023 to 2030, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 2.33 Billion in 2021 and is expected to reach USD 8.99 Billion by the end of the forecast period.

Key Points: 
  • The report also provides an in-depth analysis of the global Bio Simulation Market, including its growth prospects, market trends, and market challenges
    JERSEY CITY, N.J., April 13, 2023 /PRNewswire/ -- The global Bio Simulation Market is projected to grow at a CAGR of 16.20% from 2023 to 2030, according to a new report published by Verified Market Research®.
  • The report reveals that the market was valued at USD 2.33 Billion in 2021 and is expected to reach USD 8.99 Billion by the end of the forecast period.
  • According to a new market research report published by Verified Market Research, the global biosimulation market is expected to grow at a CAGR of 16.20% during the forecast period of 2023-2030.
  • Based on the research, Verified Market Research® has segmented the global Bio Simulation Market into Product And Services, Application, End-User, And Geography.

Cellworks Expands Into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets

Retrieved on: 
Monday, January 9, 2023
Software, Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Other Science, Molecule, Toxicity, Publication, StoneX Group Inc., AML, NGS, Daly, Biomarker, MD, Norwich Pharma Services, Drug, Drug development, Biosimulation, Patient, UnitedHealth Group, Cancer, Immortalised cell line, Clinical trial, CBM, Third-generation sequencing, Pharmaceutical industry, Medical imaging, Management

“But in many instances, the Cellworks Platform has the ability to predict the human clinical response to drug candidates years earlier than traditional development pipelines.

Key Points: 
  • “But in many instances, the Cellworks Platform has the ability to predict the human clinical response to drug candidates years earlier than traditional development pipelines.
  • Cellworks biosimulation results may provide guidance for additional indications to target for clinical development.
  • “We are well-positioned to enhance clinical markets by addressing the significant unmet needs in both precision pharma and personalized oncology.
  • I am looking forward to advancing Cellworks mission to improve patient outcomes through precision drug development and personalized therapy selection.”

Global Biosimulation Market Research Report 2022: Analysis & Forecasts 2018-2021 & 2022-2028 by Component (Software, Service), & Application (Drug Discovery, Pre-Clinical, Clinical) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Health Technology, Contract research organization, Medication, Virtual reality, Drug discovery, Drug development, Component, Artificial intelligence, Probability, USD, Nass, Software, Safety, Computer simulation, Medical device, Pharmaceutical industry, Biosimulation

The "Global Biosimulation Market (2022 Edition) - Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biosimulation Market (2022 Edition) - Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.
  • Biosimulation drug discovery offers numerous opportunities for error elimination through computer simulation, which can improve drug performance and accuracy.
  • The report analyses the Biosimulation Market by End-User (Academic & Government Research Institutes, Pharmaceutical & Biotech Companies, Contract Research Organization, Regulatory Authorities).
  • The Global Biosimulation Market has been analysed by countries (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, China, Japan, India).

Global Biosimulation Market Report 2022-2028: A $3+ Billion Market in 2021 - Focus on United States, Canada, Mexico, Germany, United Kingdom, France, Italy, China, Japan, India

Retrieved on: 
Friday, December 23, 2022
USD, Virtual reality, Component, Drug discovery, Drug development, Contract research organization, Probability, Safety, Nass, Medication, Software, Computer simulation, Artificial intelligence, Medical device, Pharmaceutical industry, Biosimulation

Global Biosimulation Market was valued at USD 3011.50 Million in the year 2021.

Key Points: 
  • Global Biosimulation Market was valued at USD 3011.50 Million in the year 2021.
  • Biosimulation drug discovery offers numerous opportunities for error elimination through computer simulation, which can improve drug performance and accuracy.
  • The report analyses the Biosimulation Market by End-User (Academic & Government Research Institutes, Pharmaceutical & Biotech Companies, Contract Research Organization, Regulatory Authorities).
  • The Global Biosimulation Market has been analysed by countries (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, China, Japan, India).

Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDS

Retrieved on: 
Monday, December 12, 2022
Software, Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Other Science, Leukemia Research, HOXA9, Lymphatic system, CEBPA, Software, Biosimulation, Society, Research, Methylation, Disease, Patient, DS, SPI1, Pearson, EZH2, Myelodysplastic syndrome, AML, MDS, Drug combination, Prognosis, Decitabine, City, University of Tennessee Health Science Center, University, DNMT3A, Abstract, Survival, NR, R, MD, Leukemia, Diagnosis, CBL, CBM, UnitedHealth Group, Student, TP53, Sequoia Capital, HMA, ASH, Versata Development Group, Inc. v. SAP America, Inc., Master of Science, Exposition, Chair, NF1, ITGAM, Haematopoietic system, Biomarker, RUNX1, Neuro, GATA1, Blood, Hypomethylating agent, NRAS, Medical imaging, Pharmaceutical industry, Hematology

In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).

Key Points: 
  • In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).
  • This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS patients.
  • This study shows that Cellworks personalized therapy biosimulation, which was based on each patients genomic aberrations, reveals a high spectrum of DS among patients with MDS.
  • The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology.

Cellworks Therapy Biosimulation Study Reveals Promising New Biomarkers for TMZ Resistance in Glioblastoma Patients

Retrieved on: 
Tuesday, November 22, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Oncology, Immunotherapy, PFS, MMR, Temozolomide, Education, Versata Development Group, Inc. v. SAP America, Inc., COSMIC, MSH6, ARID1A, CBM, Survival, Software, Neoplasm, Anomaly, Principal, Cell death, GBM, HUS, TCGA, EP300, Mutation, Neuro, Drug combination, DNA, DNA mismatch repair, Agilent Technologies, Lomustine, Biosimulation, MLH1, Survivor, Biomarker, Glioblastoma, Apoptosis, Research, Progression-free survival, TMZ, Society, Physician, Partial, Sequoia Capital, MGMT, CREBBP, EXO1, MSI, IDH, Kali Mutsa, OS, UnitedHealth Group, Gene, Patient, Pharmaceutical industry, Vaccine, MRD

The biosimulation study validated that TMZ does not trigger apoptosis in mismatch repair deficiency cancers and uncovered promising new biomarkers for TMZ resistance.

Key Points: 
  • The biosimulation study validated that TMZ does not trigger apoptosis in mismatch repair deficiency cancers and uncovered promising new biomarkers for TMZ resistance.
  • In fact, Cellworks biosimulation identifies MMR deficiency due to epigenetic, translational and proteomic silencing that leads to early progression on temozolomide despite methylated MGMT.
  • The purpose of the study was to examine the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM) using Cellworks computational biosimulation.
  • The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology.

Biosimulation Global Market to Reach $6.13 Billion by 2026

Retrieved on: 
Friday, August 26, 2022
Software, COVID-19, Contract, GDP, Centers for Medicare & Medicaid Services, Biotechnology, Toxicity, Solution, Behavior, Computer, Organization, Biobased economy, Medicare, PBPK, CAGR, Cros, Agency, Drug discovery, Growth, Drug development, Pharmaceutical industry, Fine chemical, Biosimulation

DUBLIN, Aug. 26, 2022 /PRNewswire/ --The "Biosimulation Global Market Report 2022, By Product, Application, End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 26, 2022 /PRNewswire/ --The "Biosimulation Global Market Report 2022, By Product, Application, End User" report has been added to ResearchAndMarkets.com's offering.
  • The global biosimulation market is expected to grow from $3.17 billion in 2021 to $3.64 billion in 2022 at a compound annual growth rate (CAGR) of 15.0%.
  • The market is expected to reach $6.13 billion in 2026 at a CAGR of 13.9%.
  • The biosimulation market consists of sales of biosimulation software and services by entities (organizations, sole traders, and partnerships) that are engaged in garnering a better understanding of biological processes using computer simulations.

Biosimulation Global Market Report 2022-2026: Surge in Healthcare Expenditure Worldwide is Expected to Support Significant Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 24, 2022
Health, Technology, Health Technology, Other Science, Software, Research, Science, Software, COVID-19, Contract, GDP, Biotechnology, Toxicity, Solution, Behavior, Computer, Organization, Biobased economy, Medicare, PBPK, CAGR, Cros, Agency, Drug discovery, Growth, Drug development, Pharmaceutical industry, Fine chemical, Biosimulation

The "Biosimulation Global Market Report 2022, By Product, Application, End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimulation Global Market Report 2022, By Product, Application, End User" report has been added to ResearchAndMarkets.com's offering.
  • The global biosimulation market is expected to grow from $3.17 billion in 2021 to $3.64 billion in 2022 at a compound annual growth rate (CAGR) of 15.0%.
  • The surge in healthcare expenditure worldwide is expected to support the growth of biosimulation market over the forecast period.
  • Therefore, the surge in healthcare expenditure drives the growth of the biosimulation market.